<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18349">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948310</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00045794</org_study_id>
    <nct_id>NCT01948310</nct_id>
  </id_info>
  <brief_title>Effects of Ranolazine and Exercise on Daily Physical Activity Trial</brief_title>
  <acronym>EREDA</acronym>
  <official_title>Effects of Ranolazine and Exercise on Daily Physical Activity Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess whether the increased angina threshold on ranolazine and
      subsequent higher training intensity will result in improved exercise tolerance and oxygen
      consumption; and greater than that observed with exercise training on placebo.  The study
      team anticipates the chronic exercise improvements with ranolazine will be incrementally
      higher than the acute effects provided by ranolazine alone and demonstrated in previous
      trials.  Key secondary objectives include the acute ranolazine and chronic exercise plus
      ranolazine effects on total daily energy expenditure (TDEE) and angina-related quality of
      life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in peak oxygen consumption</measure>
    <time_frame>Week 1, Week 2 and Week 13</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in treatment satisfaction as measured by the seattle angina questionnaire</measure>
    <time_frame>Week 1, Week 2 and Week 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total daily energy expenditure</measure>
    <time_frame>Week 1, Week 2 and Week 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Stable Angina</condition>
  <arm_group>
    <arm_group_label>Ranolazine plus Exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranolazine 1000mg pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Exercise</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Comparison of Ranolazine 1000mg twice per day versus placebo twice per day</description>
    <arm_group_label>Ranolazine plus Exercise</arm_group_label>
    <other_name>Renexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Aerobic Exercise</intervention_name>
    <description>Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)</description>
    <arm_group_label>Ranolazine plus Exercise</arm_group_label>
    <arm_group_label>Placebo plus Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day</description>
    <arm_group_label>Placebo plus Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented CAD diagnosis

          -  Stable angina â‰¥ 3 months

        Exclusion Criteria:

          -  Class III or IV heart failure

          -  Myocardial Infarction or coronary revascularization procedure within 2 months

          -  QT interval &gt; 500ms or prescribed medication known to prolong the QTc interval

          -  Metformin dose &gt; 1000mg/day

          -  Severe renal disease (&lt; 30ml/min creatinine clearance)

          -  Currently on dialysis

          -  Lack of transportation to the exercise and testing facilities
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William E Kraus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie H Willis, MS</last_name>
    <phone>9196606782</phone>
    <email>leslie.willis@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke Center for Living</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Willis</last_name>
      <email>leslie.willis@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>September 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
